Wells Fargo raised the firm’s price target on Axsome Therapeutics (AXSM) to $160 from $140 and keeps an Overweight rating on the shares. The ...

Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and cancer.

Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...

The "Obstructive Sleep Apnea - Global Clinical Trials Review, 2024" report has been added to ResearchAndMarkets.com's offering.This report provides top line data relating to the clinical trials on ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company has been gaining significant ...

Axsome's lead candidate, AXS-05, is currently in late-stage development for the treatment of Alzheimer's Disease Agitation (ADA). This condition affects approximately 70% of Alzheimer's patients and ...

Axsome's lead candidate, AXS-05, is currently in late-stage development for the treatment of Alzheimer's Disease Agitation (ADA). This condition affects approximately 70% of Alzheimer's patients ...

pixiv Inc. (hereinafter referred to as "pixiv," Office: Shibuya, Tokyo, Representative Director: Yasuhiro Niwa) is excited to announce a logo redesign for its illustration, manga, and novel ...